This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lagast, H
Right arrow Articles by Klastersky, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lagast, H
Right arrow Articles by Klastersky, J

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1982 October; 22(4): 604-610

Moxalactam treatment of anaerobic infections in cancer patients.

H Lagast, F Meunier-Carpentier and J Klastersky

ABSTRACT

Of 30 patients with predominantly anaerobic localized infections superimposed on chronic tissue damage related to trauma, ischemia, or tumor, 22 (73%) responded satisfactorily to moxalactam therapy. Moxalactam-resistant anaerobic pathogens emerged in two patients and were responsible for treatment failure. In six patients, two of whom also acquired resistant anaerobic pathogens, isolation of moxalactam-resistant aerobic pathogens increased during therapy.

Antimicrob Agents Chemother. 1982 October; 22(4): 604-610






Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»